Outcomes4Me

Oncology Clinical Trial Finder

Breast Cancer
Boston, MA, USA

Breast Cancer > Boston, MA, USA

(50 of 497)

Sort:

Relevance

NCT03678883

9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

Recruiting • Phase II • Stages III, IV • Post-Menopausal • Interventional

Rhode Island Hospital

Site Contact

Benedito Carneiro, MD

Benedito.Carneiro@Lifespan.org

Last Updated: 

05/25/2021

41.85 miles away from Boston, MA, USA

NCT03130439

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

Terminated • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD, MPH

Last Updated: 

11/18/2021

2.91 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD, MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT05169567

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Recruiting • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

Massachusetts General Hospital

Site Contact

617-726-2943

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021

0.55 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Site Contact

603-913-3673

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021

2.95 miles away from Boston, MA, USA


Vernon Cancer Center Pharmacy, Massachusetts General Cancer Center at Newton-Wellesley

Site Contact

617-219-1230

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021

9.79 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Site Contact

603-913-3673

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

10/21/2022

13.71 miles away from Boston, MA, USA


Massachusetts General Hospital

Site Contact

617-726-2943

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021

14.51 miles away from Boston, MA, USA

NCT02823262

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.

Completed • Phase NA • Stages 0, I, II, III • ER positive • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

Beth Israel Deaconess Medical Center

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

05/25/2021

2.73 miles away from Boston, MA, USA


Beth Israel Deaconess Medical Center

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

11/18/2021

2.75 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

11/18/2021

2.96 miles away from Boston, MA, USA

NCT00887536

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.

Completed • Phase III • Stages I, II, III • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional

Saint Anne's Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

05/25/2021

46.42 miles away from Boston, MA, USA


Hartford Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

05/25/2021

93.12 miles away from Boston, MA, USA


University of Connecticut

Principal Investigator

Norman Wolmark, MD

Last Updated: 

05/25/2021

98.93 miles away from Boston, MA, USA


University of Connecticut

Principal Investigator

Norman Wolmark, MD

Last Updated: 

11/18/2021

98.98 miles away from Boston, MA, USA

NCT04711252

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.

Recruiting • Phase III • Stage IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

10/04/2022

0.42 miles away from Boston, MA, USA

NCT03783546

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to reduce hot flashes.

Active, not recruiting • Phase NA • Stages I, II, III • ER positive • PR positive • Post-Menopausal • Brain Metastases absent • Interventional

Dana Farber Cancer Institute

Principal Investigator

Weidong Lu, PhD, MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT04379570

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.

Recruiting • Phase III • Stages I, II, III • ER positive • PR positive • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

Dana-Farber Cancer Institute

Site Contact

Site Public Contact

877-442-3324

Principal Investigator

Katherine E. Reeder-Hayes, MD

Last Updated: 

12/16/2021

2.95 miles away from Boston, MA, USA


Winchester Hospital

Site Contact

Site Public Contact

ctsucontact@westat.com

888-823-5923

Principal Investigator

Katherine E. Reeder-Hayes, MD

Last Updated: 

05/25/2021

8.01 miles away from Boston, MA, USA


Lahey Hospital and Medical Center

Site Contact

Site Public Contact

cancerclinicaltrials@lahey.org

781-744-3421

Principal Investigator

Katherine E. Reeder-Hayes, MD

Last Updated: 

05/25/2021

11.33 miles away from Boston, MA, USA


Lahey Medical Center-Peabody

Site Contact

Katherine E. Reeder-Hayes, MD

kreeder@med.unc.edu

919-445-6147

Principal Investigator

Katherine E. Reeder-Hayes, MD

Last Updated: 

05/25/2021

13.52 miles away from Boston, MA, USA


Beverly Hospital

Site Contact

Site Public Contact

978-922-3000

Principal Investigator

Katherine E. Reeder-Hayes, MD

Last Updated: 

05/25/2021

16.94 miles away from Boston, MA, USA

NCT02826434

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study is studying the safety, tolerability, and immune response of these treatments. The names of the study interventions involved in this study are: PVX-410 Vaccine Durvalumab (MEDI4736)

Active, not recruiting • Phase I • Stages I, II • ER negative • PR negative • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

Massachusetts general Hospital

Principal Investigator

Steven Isakoff, MD, PhD

Last Updated: 

02/25/2022

0.55 miles away from Boston, MA, USA


Beth Israel Deaconess Medical Center

Principal Investigator

Steven Isakoff, MD, PhD

Last Updated: 

05/25/2021

2.73 miles away from Boston, MA, USA


Beth Israel Deaconess Medical Center

Principal Investigator

Steven Isakoff, MD, PhD

Last Updated: 

11/18/2021

2.75 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Principal Investigator

Steven Isakoff, MD, PhD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Principal Investigator

Steven Isakoff, MD, PhD

Last Updated: 

11/18/2021

2.96 miles away from Boston, MA, USA

NCT03078751

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer

Completed • Phase II • Stages I, II, III • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Mass General Hospital SC

Principal Investigator

Novartis Pharmaceuticals

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Kent County Hosptial

Principal Investigator

Novartis Pharmaceuticals

Last Updated: 

05/25/2021

50.08 miles away from Boston, MA, USA


Eastern Connecticut Hematology and Oncology Associates

Principal Investigator

Novartis Pharmaceuticals

Last Updated: 

05/25/2021

77.36 miles away from Boston, MA, USA


Eastern Connecticut Hematology & Oncology Associates

Principal Investigator

Novartis Pharmaceuticals

Last Updated: 

05/25/2021

77.36 miles away from Boston, MA, USA


Baystate Medical Associates

Principal Investigator

Novartis Pharmaceuticals

Last Updated: 

05/25/2021

80.72 miles away from Boston, MA, USA

NCT02983045

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3.

Completed • Phases I, II • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases present • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Study Director

Last Updated: 

12/02/2021

2.91 miles away from Boston, MA, USA

NCT02637531

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.

Active, not recruiting • Phase I • Stages III, IV • ER negative • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional

Massachusetts General Hospital

Principal Investigator

Feng Chi, MD

Last Updated: 

11/18/2021

0.48 miles away from Boston, MA, USA


Massachusetts General Hospital

Principal Investigator

Feng Chi, MD

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Beth Israel Deaconess Medical Center

Principal Investigator

Feng Chi, MD

Last Updated: 

05/25/2021

2.73 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Principal Investigator

Feng Chi, MD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT03858322

'ADVANCE' (A Pilot Trial)

This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.

Active, not recruiting • Phase I • Stages I, II, III • ER negative • Post-Menopausal • Brain Metastases absent • Interventional

Dana Farber Cancer Institute

Principal Investigator

Rachel Freedman, MD, MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA


Brigham and Women's Hospital

Principal Investigator

Rachel Freedman, MD, MPH

Last Updated: 

05/25/2021

2.96 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Principal Investigator

Rachel Freedman, MD, MPH

Last Updated: 

11/18/2021

2.96 miles away from Boston, MA, USA


Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital

Principal Investigator

Rachel Freedman, MD, MPH

Last Updated: 

05/25/2021

13.71 miles away from Boston, MA, USA


Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center

Principal Investigator

Rachel Freedman, MD, MPH

Last Updated: 

05/25/2021

28.75 miles away from Boston, MA, USA

NCT03063619

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Active, not recruiting • Phase II • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Banu Arun, MD

Last Updated: 

12/06/2021

2.95 miles away from Boston, MA, USA

NCT03471663

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate preliminary anti-tumor activities in women with advanced or metastatic ER-positive, HER2-negative breast cancer.

Active, not recruiting • Phase I • Stages III, IV • ER positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Local Institution

Last Updated: 

02/09/2023

0.3 miles away from Boston, MA, USA

NCT04278144

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Recruiting • Phases I, II • Stages III, IV • HER2 positive • Post-Menopausal • Interventional

Dana-Farber Cancer Institute

Site Contact

DFCI Clinical Trials Hotline

877-338-7425

Principal Investigator

Bolt Clinical Development

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT03959891

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

This research is looking to find out if the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant can be an effective treatment for breast cancer.

Active, not recruiting • Phase I • Stages III, IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

Massachusetts General Hospital Cancer Center

Principal Investigator

Aditya Bardia, MD

Last Updated: 

11/18/2021

0.55 miles away from Boston, MA, USA


Massachusetts General Hospital Cancer Center

Principal Investigator

Aditya Bardia, MD

Last Updated: 

11/18/2021

0.55 miles away from Boston, MA, USA


Massachusetts General Hospital Cancer Center

Principal Investigator

Aditya Bardia, MD

Last Updated: 

05/03/2022

0.56 miles away from Boston, MA, USA

NCT05423730

Alcohol and Breast Cancer (ABC) Trial

This research study is a pilot study, which is the first time investigators are examining the effect of light alcohol consumption on sex hormones among postmenopausal women with estrogen receptor-positive (ER+) breast cancer taking an aromatase inhibitor The names of the study exposures involved in this study are: White wine White grape juice

Recruiting • Phase NA • Stages 0, I, II, III, IV • ER positive • Surgical • Post-Menopausal • Interventional

Beth Israel Deaconess Medical Center

Site Contact

Kenneth Mukamal, MD, MPH

kmukamal@bidmc.harvard.edu

617-754-1409

Principal Investigator

Kenneth Mukamal, MD, MPH

Last Updated: 

06/22/2022

2.73 miles away from Boston, MA, USA

NCT02860000

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.

Active, not recruiting • Phase II • Stages III, IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Tufia Haddad

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT04478266

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: To compare the overall survival in both treatment arms To evaluate the objective response rate in both treatment arms To evaluate the duration of response in both treatment arms To evaluate the clinical benefit rate in both treatment arms To evaluate progression-free survival on next line of therapy To evaluate the pharmacokinetics of amcenestrant, and palbociclib To evaluate health-related quality of life in both treatment arms To evaluate the time to first chemotherapy in both treatment arms To evaluate safety in both treatment arms

Active, not recruiting • Phase III • Stages III, IV • ER positive • HER2 negative • CDK4/6 inhibitor absent • Medical Oncology • Post-Menopausal • Interventional

Investigational Site Number 8400002

Principal Investigator

Clinical Sciences & Operations

Last Updated: 

05/25/2021

0.46 miles away from Boston, MA, USA


Investigational Site Number :8400017

Principal Investigator

Clinical Sciences & Operations

Last Updated: 

05/03/2022

0.46 miles away from Boston, MA, USA


Investigational Site Number 8400015

Principal Investigator

Clinical Sciences & Operations

Last Updated: 

05/25/2021

2.11 miles away from Boston, MA, USA


Investigational Site Number :8400015

Principal Investigator

Clinical Sciences & Operations

Last Updated: 

10/02/2021

2.11 miles away from Boston, MA, USA


Investigational Site Number :8400077

Principal Investigator

Clinical Sciences & Operations

Last Updated: 

10/02/2021

7.84 miles away from Boston, MA, USA

NCT02657343

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment. This research study is a way of gaining new knowledge about the combination of Ribociclib with other drugs as a possible treatment for this diagnosis.

Completed • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional

Massacusetts General Hospital

Principal Investigator

Sara Tolaney, MD MPH

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT02939274

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metastases of breast cancer for which no curative or significantly palliative therapy exists, including chest wall therapy.

Unknown status • Phase II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional

Massachusetts General Hospital

Site Contact

Steven J Isakoff, MD PhD

617-726-4920

Principal Investigator

Steven J Isakoff, MD PhD

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Site Contact

Beth Overmoyer, MD

617-632-3800

Principal Investigator

Steven J Isakoff, MD PhD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT03058289

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also plans to test INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.

Completed • Phases I, II • Stages III, IV • Post-Menopausal • Brain Metastases present • Interventional

UMASS Memorial Medical Center

Principal Investigator

Ian B. Walters, M.D.

Last Updated: 

05/25/2021

36.35 miles away from Boston, MA, USA

NCT03997968

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Recruiting • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional

Massachusetts General Hospital

Site Contact

Dejan Juric, MD

djuric@partners.org

617-724-4000

Principal Investigator

Judson Englert, MD

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Site Contact

877-338-7425

Principal Investigator

Judson Englert, MD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Site Contact

877-338-7425

Principal Investigator

Judson Englert, MD

Last Updated: 

11/18/2021

2.96 miles away from Boston, MA, USA

NCT04072952

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.

Recruiting • Phases I, II • Stages III, IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

Clinical Trial Site

Site Contact

Arvinas Estrogen Receptor, Inc.

clinicaltrialsARV-471@arvinas.com

475-345-3366

Last Updated: 

02/12/2022

0.13 miles away from Boston, MA, USA


Massachusetts General Hospital

Site Contact

Arvinas Estrogen Receptor, Inc.

clinicaltrialsARV-471@arvinas.com

475-345-3366

Last Updated: 

01/23/2023

0.55 miles away from Boston, MA, USA


Clinical Trial Site

Site Contact

Arvinas Estrogen Receptor, Inc.

clinicaltrialsARV-471@arvinas.com

475-345-3366

Last Updated: 

02/12/2022

3.1 miles away from Boston, MA, USA

NCT04682431

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

Recruiting • Phase I • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

Massachusetts General Hospital

Site Contact

Denise Deegan

ddeegan@pionyrtx.com

650-825-6140

Principal Investigator

Len Reyno, MD

Last Updated: 

10/17/2022

0.55 miles away from Boston, MA, USA

NCT03601897

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.

Active, not recruiting • Phases I, II • Stage IV • Medical Oncology • Post-Menopausal • Interventional

Dana-Farber

Last Updated: 

05/25/2021

2.96 miles away from Boston, MA, USA

NCT04538742

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

Recruiting • Phases I, II • Stages III, IV • Post-Menopausal • Brain Metastases present • Interventional

Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

01/13/2022

41.46 miles away from Boston, MA, USA

NCT04244552

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.

Recruiting • Phase I • Stages III, IV • PR negative • HER2 negative • Post-Menopausal • Interventional

Massachusetts General Hospital

Site Contact

Nick Higgins

nhiggins@atreca.com

650-453-5279

Principal Investigator

Sudha Khurana, PhD

Last Updated: 

03/11/2022

0.55 miles away from Boston, MA, USA

NCT01975831

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment. The primary study objective was to determine the maximum tolerated dose (MTD) and safety profile of the durvalumab and tremelimumab combination. Secondary objectives were to evaluate the pharmacokinetics (PK) and immunogenicity of durvalumab and tremelimumab, and the antitumor activity (tumor response, progression-free survival [PFS], and overall survival [OS]) of the durvalumab and tremelimumab combination. (Note: Collection of PK and immunogenicity samples was removed by amendment; analysis was not done.) Exploratory objectives were to evaluate the biological activity of the durvalumab and tremelimumab combination.

Completed • Phase I • Stages III, IV • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Jedd D Wolchok, MD, PhD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT02498613

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

Active, not recruiting • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Joseph W Kim

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT02623972

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.

Active, not recruiting • Phase II • Stages I, II, III • HER2 negative • Post-Menopausal • Interventional

Brigham and Women's Hospital

Principal Investigator

Filipa Lynce, MD

Last Updated: 

11/18/2021

2.95 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Principal Investigator

Filipa Lynce, MD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA


Brigham and Women's Hospital

Principal Investigator

Filipa Lynce, MD

Last Updated: 

05/25/2021

2.96 miles away from Boston, MA, USA

NCT05104866

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.

Active, not recruiting • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases present • Interventional

Research Site

Last Updated: 

11/18/2021

0.42 miles away from Boston, MA, USA


Research Site

Last Updated: 

11/18/2021

2.35 miles away from Boston, MA, USA


Research Site

Last Updated: 

04/23/2022

40.33 miles away from Boston, MA, USA

NCT02163694

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2 (BRCA1; BRCA2) mutation in Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic or locally advanced unresectable breast cancer. The secondary objectives of the study are to assess overall survival (OS), clinical benefit rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS on subsequent therapy (PFS2) in participants treated with veliparib in combination with C/P versus placebo in combination with C/P.

Active, not recruiting • Phase III • Stages III, IV • HER2 negative • Somatic BRCA1/2 present • Post-Menopausal • Interventional

UMass Memorial Medical Center /ID# 129067

Principal Investigator

ABBVIE INC.

Last Updated: 

06/16/2021

36.36 miles away from Boston, MA, USA


UMass Chan Medical School /ID# 129067

Principal Investigator

ABBVIE INC.

Last Updated: 

01/25/2022

36.4 miles away from Boston, MA, USA


Baystate Medical Center /ID# 139461

Principal Investigator

ABBVIE INC.

Last Updated: 

06/16/2021

80.72 miles away from Boston, MA, USA

NCT02734004

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

Active, not recruiting • Phases I, II • Stages III, IV • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Research Site

Principal Investigator

Susan Domchek, MD

Last Updated: 

11/18/2021

0.42 miles away from Boston, MA, USA

NCT01905592

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice

Terminated • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Interventional

GSK Investigational Site

Principal Investigator

GSK Clinical Trials

Last Updated: 

11/18/2021

0.6 miles away from Boston, MA, USA


GSK Investigational Site

Principal Investigator

GSK Clinical Trials

Last Updated: 

05/25/2021

1.76 miles away from Boston, MA, USA

NCT02296801

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been treated. Letrozole is a type of endocrine therapy called an aromatase inhibitor (AI) and is standard treatment for post-menopausal women with ER-positive/HER2-negative breast cancer.

Completed • Phase II • Stages I, II • Medical Oncology • Post-Menopausal • Interventional

Women and Infants Hospital of Rhode Island

Principal Investigator

Norman Wolmark, MD

Last Updated: 

05/25/2021

42.05 miles away from Boston, MA, USA

NCT03584009

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, locally advanced or Metastatic Breast Cancer (MBC) who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks. As of 9th October 2020, participants in the Venetoclax + Fulvestrant arm, have all discontinued Venetoclax treatment and have continued on Fulvestrant treatment alone.

Terminated • Phase II • Stages III, IV • ER positive • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Massachusetts General Hospital.

Principal Investigator

Clinical Trials

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Mass General/North Shore Cancer

Principal Investigator

Clinical Trials

Last Updated: 

11/18/2021

14.51 miles away from Boston, MA, USA


Mass General/North Shore Cancer

Principal Investigator

Clinical Trials

Last Updated: 

05/25/2021

14.51 miles away from Boston, MA, USA

NCT03316586

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: Cabozantinib (XL184) Nivolumab

Completed • Phase II • Stage IV • ER negative • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD, MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT02338349

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer.

Completed • Phase I • Stages III, IV • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Radius Pharmaceuticals, Inc.

Principal Investigator

Sr. Director, Clinical Operations

Last Updated: 

05/25/2021

11.37 miles away from Boston, MA, USA

NCT03945721

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

This research study involves Niraparib as a possible treatment for triple negative breast cancer.

Recruiting • Phase I • Stages I, II, III • ER negative • PR negative • HER2 negative • Radiation • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional

Massachusetts General Hospital Cancer Center

Site Contact

Alice Ho, MD

alice.ho@mgh.harvard.edu

617-724-1160

Principal Investigator

Alice Ho, MD

Last Updated: 

05/03/2022

0.56 miles away from Boston, MA, USA


Dana Farber Cancer Institute/Brigham and Women's Hospital

Site Contact

Jennifer Bellon, MD

jbellon@lroc.harvard.edu

Principal Investigator

Alice Ho, MD

Last Updated: 

05/25/2021

2.93 miles away from Boston, MA, USA

NCT03573661

A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers

The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.

Completed • Phase O • Stages 0, I, II, III • Post-Menopausal • Brain Metastases absent • Interventional

Lahey Hospital & Medical Center (Lahey Clinic)

Principal Investigator

Richard J Barth, Jr., MD

Last Updated: 

05/25/2021

11.34 miles away from Boston, MA, USA


St. Joseph Hospital

Principal Investigator

Richard J Barth, Jr., MD

Last Updated: 

11/18/2021

34.37 miles away from Boston, MA, USA


Cheshire Medical Center

Principal Investigator

Richard J Barth, Jr., MD

Last Updated: 

05/25/2021

74.67 miles away from Boston, MA, USA

NCT02129686

A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients

This study is being done to evaluate the potential benefits of using acupuncture to reduce symptoms of tingling, burning, numbness and pain in the hands and feet of women with peripheral neuropathy after completion of chemotherapy for breast cancer.

Completed • Phase NA • Stages I, II, III • ER negative • Surgical • Post-Menopausal • Interventional

Dana Farber Cancer Institute

Principal Investigator

Weidong Lu, M.B., MPH, Ph.D

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA


Dana Farber Cancer Institute

Principal Investigator

Weidong Lu, M.B., MPH, Ph.D

Last Updated: 

11/18/2021

2.96 miles away from Boston, MA, USA

NCT03822312

A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy

This research study is evaluating whether the use of digital breast tomosynthesis and near-infrared tomographic optical breast imaging (DBT-TOBI) scans can predict the response of triple negative or HER2+ breast cancer to neoadjuvant chemotherapy. The study radiologic scan involved in this study is digital breast tomosynthesis (also called 3 Dimensional mammogram) combined with near-infrared tomographic optical breast imaging, or DBT-TOBI.

Active, not recruiting • Phase NA • Stages I, II, III • Post-Menopausal • Brain Metastases absent • Interventional

Massachusetts General Hospital Cancer Center

Principal Investigator

Steven J Isakoff, MD

Last Updated: 

11/18/2021

0.55 miles away from Boston, MA, USA


Massachusetts General Hospital Cancer Center

Principal Investigator

Steven J Isakoff, MD

Last Updated: 

05/25/2021

0.56 miles away from Boston, MA, USA

NCT03051659

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.

Active, not recruiting • Phase II • Stage IV • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional

Massachusetts General Hospital

Principal Investigator

Sara Tolaney, MD MPH

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Beth Israel Deaconess Medical Center

Principal Investigator

Sara Tolaney, MD MPH

Last Updated: 

05/25/2021

2.73 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD MPH

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT01921335

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

The purpose of this study is to test the safety of different doses of ARRY-380 in combination with trastuzumab. Trastuzumab is an FDA approved drug for the treatment of HER2 metastatic breast cancer. However, the combination of ARRY-380 and trastuzumab has not yet been tested. Both agents block the HER2 receptor, which is thought to be overactive in HER2-positive breast cancer. It is thought that ARRY-380 and trastuzumab might work together because they attach to different parts of the HER2 receptor and prevent it from functioning. Because HER2 positive breast cancer contains high levels of HER2 receptor, but normal cells in your body generally do not, the drugs may be able to "target" the cancer cells. In addition, in laboratory studies, ARRY-380 appears to have some penetration into the brain.

Active, not recruiting • Phase I • Stage IV • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional

Massachusetts General Hospital

Principal Investigator

Nancy Lin, MD

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Dana-Farber Cancer Institute

Principal Investigator

Nancy Lin, MD

Last Updated: 

05/25/2021

2.95 miles away from Boston, MA, USA

NCT04829604

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd

Active, not recruiting • Phase II • Stage IV • Post-Menopausal • Brain Metastases present • Interventional

Research Site

Principal Investigator

Ambrx

Last Updated: 

07/26/2022

2.35 miles away from Boston, MA, USA

NCT05091528

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2). Participants will be enrolled into each Arm based on cancer diagnosis and prior therapies.

Terminated • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional

Massachusetts General Hospital

Principal Investigator

Naomi Hunder, MD

Last Updated: 

01/20/2022

0.55 miles away from Boston, MA, USA

NCT05234606

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4 expression.

Recruiting • Phases I, II • Stages III, IV • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Massachusetts General Hospital

Site Contact

Clinical Trials Operations

ClinOps@Silverbacktx.com

206 456-2900

Principal Investigator

Natasha Angra, PharmD

Last Updated: 

02/11/2022

0.55 miles away from Boston, MA, USA

NCT00781612

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.

Recruiting • Phase II • Stage IV • HER2 positive • Medical Oncology • Post-Menopausal • Interventional

Massachusetts General Hospital

Site Contact

Reference Study ID Number: BO25430 www.roche.com/about_roche/roche_worldwide.htm

global-roche-genentech-trials@gene.com

Last Updated: 

05/25/2021

0.55 miles away from Boston, MA, USA


Dana Farber Cancer Institute; Breast Oncology

Site Contact

Reference Study ID Number: BO25430 www.roche.com/about_roche/roche_worldwide.htm

global-roche-genentech-trials@gene.com

Last Updated: 

05/25/2021

2.96 miles away from Boston, MA, USA


New England Cancer Specialists

Site Contact

Reference Study ID Number: BO25430 www.roche.com/about_roche/roche_worldwide.htm

global-roche-genentech-trials@gene.com

Last Updated: 

05/25/2021

93.53 miles away from Boston, MA, USA

Outcomes4Me

© 2023 Outcomes4Me Inc. All rights reserved.

14
7
12
1
1
1
2
1
1
1
5
1
1
2
1
1
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
2
1
5
2
1
1
3
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1